A comprehensive view of Biogen Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

FDA advisor committee supports conditional clearance of Biogen’s tofersen ALS drug; tofersen treats ALS caused by SOD1 gene mutation, which is estimated to be responsible for less than 500 of the approximately 30,000 ALS cases in the US
Published: March 23, 2023 by BioPharma Dive
FDA grants accelerated approval to Biogen and Eisai's anti-amyloid beta protofibril antibody candidate Leqembi lecanemab to treat early Alzheimer's disease; Eisai has set wholesale acquisition cost for the drug at US$26,500 per year
Published: January 10, 2023 by Zack's Commentary
Biogen picks Christopher Viehbacher, former leader of Sanofi, as new CEO to replace Michel Vounatsos, who is stepping down from the job; Viehbacher previously headed healthcare investment fund Gurnet Point Capital
Published: November 10, 2022 by Boston Globe, The (MA)
Biogen reports Q3 net income up at US$1.1B from US$329.2M a year ago due to drop in expenses and US$503.7M from sale of building; revenue down 10% from a year ago to US$2.5B due to decreased revenue from multiple sclerosis drugs, biosimilars, Spinraza
Published: October 27, 2022 by SeeNews Pharmaceuticals
Biogen reports Q3 GAAP net income up at US$1.1B from US$329.2M a year ago, with revenue down 10% from a year ago to US$2.5B; multiple sclerosis drug Ocrevus sales down 11% year-over-year to US$1.6B, biosimilar sales down 7% from a year ago to US$188.0M
Published: October 25, 2022 by U.S. Regulated Equity Markets (Alternative Disclosure) via PUBT

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count